44results about How to "To achieve the purpose of healing" patented technology

The invention provides a medicine for curing stomach illness and duodenum ulceration. The medicine is prepared by the following raw materials: zanthoxylum nitidum, rhizoma corydalis, common aucklandia root, myrrh, fruit of medicinal evodia, cherokee rose root, nutgrass flastedge, edicated leaven, fumitory, thickleaf croton root, white peony root, licorice, dandelion, gentiana scabra bge, malt, tambac, scandent schefflera stem and leaf, endothelium corneum gigeriae galli, rhizoma atractylodis, magnolia officinalis, radix-polygoni multiflori, tuckahoe, cassia twig, amomum villosum and rhizoma ligustici wallichii. The medicine is prepared by taking the traditional Chinese medicinal herbs as raw materials, scientific formulation and the repeated verification of clinical trail and is in line with the theory of the traditional Chinese medicine. The medicine has the prominent effects of no toxic and side effects, rapidly relieving diseases of patients, high cure rate, being difficult to recur, therefore, the medicine has good social benefits after being widely popularized.

The present invention discloses an anti-CD19 fully human antibody or antibody fragment as well as methods and applications thereof. The antibody or antibody fragment comprises: a heavy chain and a light chain; the heavy chain and the light chain comprise a variable region, and the variable region comprises a complementary decision area. The complementarity determining regions CDR1, CDR2 and CDR3 of the heavy chain are represented by HCDR1, HCDR2 and HCDR3 respectively; the complementarity determining regions CDR1, CDR2 and CDR3 of the light chain are represented by LCDR1, LCDR2 and LCDR3 respectively; the amino acid sequence of HCDR1 includes SEQ ID NO: 3 The amino acid sequence of HCDR2 includes SEQ ID NO: 4; the amino acid sequence of HCDR3 includes SEQ ID NO: 5; the amino acid sequence of LCDR1 includes SEQ ID NO: 6; the amino acid sequence of LCDR2 includes DVS; the amino acid sequence of LCDR3 includes SEQ ID NO: 7. The antibody or antibody fragment of the present invention can bind to human CD19 protein with high specificity, and the chimeric antigen receptor T cell technology is used to engineer expression and integration in T cells, and the obtained chimeric antigen receptor T cells can be used for treatment Hematologic cancers associated with CD19 expression.

The invention relates to a novel therapy for treating rheumatoid bone diseases and advanced cancer pain by utilizing a biological needle and a biological enzyme medicated thread, and belongs to the technical field of pain treatment. The novel therapy comprises the following steps: selecting meridians and collaterals, acupuncture points and therapy points according to different disease symptoms, and marking by iodophor; preparing a needed biological needle; inserting the biological enzyme medicated thread from a needle head end hole of a trocar of the biological needle and pushing the biological enzyme medicated thread into the middle part of a protection sleeve of the trocar; dipping a needle tip of the trocar into medical liquid; combusting on an alcohol lamp for 1 to 2 seconds; then dipping in medical powder and continually combusting for 1 to 2 seconds; rapidly stabbing a combusted needle head into one therapy point; planting the biological enzyme medicated thread in the sleeve of the trocar into an acupuncture point of a human body by pushing a needle core through a pintle, and injecting a related hydro-acupuncture medicament for carrying out adjuvant therapy. The novel therapy provided by the invention is finished through utilizing needle stabbing and medicine administration on acupuncture points of diseases and pains, and the diseases and pains are radically removed; the pains of patients with cancer pains are rapidly alleviated and the life of the patients with the cancer pains can be properly prolonged, so that the novel therapy is good news for patients with the rheumatoid bone diseases and patients with advanced cancer.

The invention relates to medicine for treating ischemic stroke and sequela thereof, which is the medicine prepared by taking Chinese herbal medicine as raw materials for treating ischemic stroke. The prior Chinese patent medicine and western medicine for treating ischemic stroke can only control or relieve the deterioration and the development of illness state, and have no ideal effect for the recovery of the illness and sequela. The medicine for treating ischemic stroke and sequela is characterized by being prepared from the following raw materials by weight: 230 to 250 portions of milk veteh, 15 to 17 portions of Chinese angelica, 15 to 17 portions of Szechuan Lovage Rhizome, 15 to 17 portions of prepared rhizome of rehmannia, 25 to 27 portions of radix paeonia alba, 15 to 17 portions of red paeonia, 5 to 7 portions of peach kernel, 5 to 7 portions of safflower, 25 to 27 portions of white atractylodes rhizome, 25 to 27 portions of tuckahoe, 11 to 13 portions of liquorice, 6 to 7 portions of ginseng and 9 to 11 portions of cordyceps sinensis.

The invention discloses an external Chinese medicine lotion for preventing and treating onychomycosis and a preparation method thereof. It consists of the following raw materials in parts by weight: 20 to 30 parts of propolis, 15 to 20 parts of Toosendan, 20 to 25 parts of rhododendron, 20 to 30 parts of viola, 15 to 30 parts of camphor leaves, and 20 parts of Sophora flavescens ~30 parts, Sichuan pepper 20~25 parts, alum 20~30 parts, aloe vera 20~25 parts, nepeta 20~30 parts, wormwood 20~30 parts, scutellaria baicalensis 10~20 parts, volume fraction 75% ethanol 1000~ 1500 parts, white vinegar 1000-1500 parts. The external Chinese medicine lotion for preventing and treating onychomycosis of the present invention can soften and remove diseased nails, is beneficial to directly reach the lesion, treat both symptoms and root causes, eliminate clinical manifestations, and finally achieve the purpose of curing, and has good therapeutic effect and is not easy to relapse.

The invention discloses a Chinese medicinal preparation for treating viral conjunctivitis, which consists of the following traditional Chinese medicine raw materials in part by weight: the rhizome of Chinese goldthread, lonicera flower, smoked plum, Chinese parsnip root, selfheal, fructus forsythiae, isatis root, folium isatidis, radix bupleuri, tribulus terrestris, periostracum cicada, dandelion, akebia stem, radices trichosanthis and radix scrophulariae. The Chinese medicinal preparation disclosed by the invention is prepared through syndrome differentiation of traditional Chinese medicine on the viral conjunctivitis and repeated clinical prescription compatibility; after a patient takes the Chinese medicinal preparation disclosed by the invention, yin and yang are balanced by invigorating qi and blood, dispelling wind and clearing heat, reinforcing immunity of the organism of a patient and regulating and nourishing to recover functions of liver, kidney, spleen and stomach so as to dissipate pathogenic qi, warm meridians, dilate vessels, improve local blood circulation, promote inflammation absorption, enable qi and blood to be sufficient, enable symptoms to be self-removed and heal the viral conjunctivitis. Moreover, the Chinese medicinal preparation disclosed by the invention does not generate drug resistance, has no toxic or side effects and has one course of treatment of 7 days; after the patient takes the Chinese medicinal preparation for one to two courses of treatment, the viral conjunctivitis can be cured; and the statistic data of clinically treating the viral conjunctivitis shows that the effective rate reaches over 98 percent.

The invention relates to multi-effect traditional Chinese medicine formula for quickly eliminating chronic lung diseases and a preparation method of the multi-effect traditional Chinese medicine formula. According to the formula, cordyceps sinensis, fritillaria cirrhosa, gecko, schisandra chinensis, buffla horn wire and pearl are used as monarch drug, tonification and purgation in combination is used as the first strategy, two groups of ministerial drugs are additionally added to treat both symptoms and root causes, and the chronic lung diseases are eliminated in three manners, so that the multi-effect traditional Chinese medicine formula is fast and multi-effective. The total efficiency of the formula for treating bronchial asthma is 83%, the total efficiency of emphysema is 86%, the total efficiency of bronchitis is 89%, and the total efficiency of severe cough is 91%.

The present invention is one kind of Chinese medicine for treating psoriasis and preventing its recurrence. The Chinese medicine is prepared with aweto 15-25 (in weight portions, the same below), ginseng 5-6, pilose antler 4-5, tuckahoe 25-35, tree peony bark 25-35, Chuanxiong rhizome 35-55, cassia 25-35, angelica 35-45, and astragalus root 40-60.